Access to high cost medicines in Australia: ethical perspectives
- PMID: 18489760
- PMCID: PMC2412887
- DOI: 10.1186/1743-8462-5-4
Access to high cost medicines in Australia: ethical perspectives
Abstract
Access to "high cost medicines" through Australia's Pharmaceutical Benefits Scheme (PBS) is tightly regulated. It is inherently difficult to apply any criteria-based system of control in a way that provides a fair balance between efficient use of limited resources for community needs and equitable individual access to care. We suggest, in relation to very high cost medicines, that the present arrangements be re-considered in order to overcome potential inequities. The biological agents for the treatment of rheumatoid arthritis are used as an example by which to discuss the ethical issues associated with the current scheme. Consideration of ethical aspects of the PBS and similar programs is important in order to achieve the fairest outcomes for individual patients, as well as for the community.
References
-
- Commonwealth Department of Health and Aged Care The Australian Health Care System, An Outline. 2000.
-
- Beauchamp TL, Childress JF. Justice. In: Beauchamp TL and Childress JF, editor. Principles of Biomedical Ethics. 5th. New York, Oxford University Press; 2001. pp. 225–282.
-
- High Cost Drugs Working Party Drug and Therapeutics Committee Template for Formulary Submissions - Decision algorithm. http://www.ciap.health.nsw.gov.au/nswtag/high_cost_drugs-wp.html (cited 12 Oct 2006)
-
- Australian Government Department of Health and Ageing Pharmaceutical Benefits Scheme: Outcomes of Pharmaceutical Benefits Advisory Committee meetings. http://www.aodgp.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-... (cited 29 Dec 2007)
Publication types
LinkOut - more resources
Full Text Sources